Please use this identifier to cite or link to this item:
Title: Imidazo[1,2-a]pyridine Derivatives as Aldehyde Dehydrogenase Inhibitors: Novel Chemotypes to Target Glioblastoma Stem Cells
Authors: Quattrini, Luca
Gelardi, Edoardo Luigi Maria
Coviello, Vito
Sartini, Stefania
Ferraris, Davide
Mori, Mattia 
Nakano, Ichiro
Garavaglia, Silvia
La Motta, Concettina
Issue Date: 2020
Project: None 
Glioblastoma multiforme (GBM) is the deadliest form of brain tumour. It is known for its ability to escape the therapeutic options available to date, thanks to the presence of a subset of cells endowed with stem-like properties and able to resist to cytotoxic treatments. As the cytosolic enzyme aldehyde dehydrogenase 1A3 turns out to be overexpresses in this kind of cells, playing a key role for their vitality, treatments targeting this enzyme may represent a successful strategy to fight GBM. In this work we describe a novel class of imidazo[1,2-a]pyridine derivatives as aldehyde dehydrogenase 1A3 inhibitors, reporting the evidence of their significance as novel drug candidates for the treatment of GBM. Besides showing an interesting functional profile, in terms of activity against the target enzyme and selectivity toward highly homologous isoenzymes, representative examples of the series showed also a nanomolar to picomolar efficacy against patient-derived GBM stem-like cells, thus proving the concept that targeting aldehyde dehydrogenase might represent a novel and promising way to combat GBM by striking its ability to divide immortally.
ISSN: 0022-2623
DOI: 10.1021/acs.jmedchem.9b01910
Appears in Collections:Publications

Show full item record

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.